Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

NCT01433731 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, T-Cell, Cutaneous

Interventions

DRUG: placebo for SHAPE (SHP-141)
DRUG: SHAPE (SHP-141) 0.1% BID
DRUG: SHAPE (SHP-141) 0.5% BID
DRUG: SHAPE (SHP-141) 1.0% BID

Sponsor

TetraLogic Pharmaceuticals

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]